^
Association details:
| Biomarker: | FLT3 D835V |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
Excerpt:
Substitution of the FLT3 “gatekeeper” phenylalanine with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance. Saturation mutagenesis of FLT3-ITD exclusively identified FLT3 AL mutations at positions D835, D839, and Y842.
DOI:
https://dx.doi.org/10.1182%2Fblood-2012-07-442871
